Kura Oncology, Inc. (KURA) |
|
11.62 0.91 (8.5%)
|
05-16 07:33 |
|
Open: |
11.06 |
Pre. Close: |
10.71 |
|
High:
|
11.63 |
Low:
|
10.91 |
|
Volume:
|
650,058 |
Market Cap:
|
774(M) |
|
|
|
|
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.65 - 11.71 |
11.71 - 11.77 |
|
Low:
|
10.74 - 10.83 |
10.83 - 10.9 |
|
Close:
|
11.49 - 11.62 |
11.62 - 11.73 |
|
Technical analysis |
as of: 2022-05-13 4:39:29 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 16.92 One year: 19.86 |
| Support: |
Support1: 10.4 Support2: 8.66 |
| Resistance: |
Resistance1: 14.48 Resistance2: 17.01 |
| Pivot: |
13.27  |
| Moving Average: |
MA(5): 11.42 MA(20): 13.85
MA(100): 14.56 MA(250): 16.93 |
| MACD: |
MACD(12,26): -1.2 Signal(9): -0.9 |
| Stochastic oscillator: |
%K(14,3): 10.4 %D(3): 11 |
| RSI: |
RSI(14): 35.6 |
| 52-week: |
High: 24.59 Low: 10.4 |
| Average Vol(K): |
3-Month: 621 (K) 10-Days: 752 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KURA ] has closed above bottom band by 23.7%. Bollinger Bands are 101% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue. |
|
|
Headline News |
Wed, 11 May 2022
Restaurant Roundup: Former HopCat space ready to open as Italian restaurant, Kura Sushi in Novi and more - Crain's Detroit Business
Wed, 11 May 2022
Kura Oncology (NASDAQ:KURA) Upgraded by StockNews.com to Hold - Defense World
Tue, 10 May 2022
Steven Benrubi retires as Kura Sushi CFO - Restaurant Business Online
Thu, 05 May 2022
Kura Sushi to Open Second Michigan Location in Novi This Summer - dbusiness.com
Thu, 05 May 2022
There's treasures in store at Japanese Kitchen Kura - pentictonherald.ca
Wed, 04 May 2022
Kura Oncology: Q1 Earnings Snapshot - Beaumont Enterprise
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
67 (M) |
| Shares Float |
50 (M) |
|
% Held by Insiders
|
2.9 (%) |
|
% Held by Institutions
|
105.2 (%) |
|
Shares Short
|
3,540 (K) |
|
Shares Short P.Month
|
3,760 (K) |
Stock Financials |
|
EPS
|
-1.92 |
|
EPS Est Next Qtl
|
-0.38 |
|
EPS Est This Year
|
-1.53 |
|
EPS Est Next Year
|
-1.89 |
|
Book Value (p.s.)
|
8.02 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-17.3 |
|
Return on Equity (ttm)
|
-29.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.87 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-99 (M) |
|
Levered Free Cash Flow
|
-58 (M) |
Stock Valuations |
|
PE Ratio
|
-6.06 |
|
PEG Ratio
|
-0.4 |
|
Price to Book value
|
1.44 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-7.78 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
